One sentence summary: Vectors based on bacterial or P1-derived artificial chromosomes, on transformation-associated and on integrase-mediated recombination, developed for capturing and heterologous expression of large biosynthetic gene clusters for new bioactive compound discovery and production.
INTRODUCTION
Bioactive compounds of microbial origin with their structural novelty, diversity and complexity are still an invaluable source for drug discovery and development (Monciardini et al. 2014; Genilloud 2017) . The exponential increase in available microbial genome sequences coupled with predictive bioinformatic tools are underscoring the genetic capacity of bacteria to produce an unexpected large number of specialized compounds. However, only a small fraction of these compounds can be detected in the laboratory, since most of the corresponding biosynthetic genes are silent or poorly expressed under conventional laboratory culture conditions (Rutledge and Challis 2015; Blin et al. 2017; Tracanna et al. 2017) . While the organization of genes in biosynthetic gene clusters (BGCs) facilitates their identification and engineering, these approaches are often hampered by lack of or limited genetic tractability of the producing microrganisms (Galm and Shen 2006; Rutlege and Challis 2015) . Thus, standard approaches such as overexpression of a cluster-associated activator, deletion of a cluster-associated repressor, replacement of natural promoters with constitutive or inducible promoters, or overexpression of pathway precursors are not immediately applicable to most microbial strains. Devising methods to genetically manipulate a microbial strain with interesting BGC(s) can be a lengthy and sometime unsuccessful endeavor. This is particularly true for actinomycetes, the main producers of secondary metabolites and the focus of this minireview.
Important research tools for genome projects were developed in the 1990s, when DNA sequencing heavily depended on producing high-quality libraries, particularly large-insert libraries, well before the introduction of next-generation sequencing (NGS) and the deluge of microbial genome sequences. Relevant tools were yeast artificial chromosomes (YACs) for cloning and assembling large DNA fragments (Monaco and Larin 1994) and artificial chrosomomes for replication in bacteria (Shizuya et al. 1992; Ioannou et al. 1994) . The latters were distinguished on the basis of the replicon they employed and named BAC and PAC if they relied on plasmid F1-or bacteriophage P1-derived replicon, respectively. YAC, BAC and PAC vectors could easily accommodate DNA inserts exceeding 100 kbp.
The logical step was then to combine BAC or PAC vectors with genetic elements that allowed their introduction in suitable actinomycete hosts. One of the early examples is represented by the PAC-derived Escherichia coli-Streptomyces shuttle vectors, designated ESACs, constructed for antibiotic-producing actinomycetes (Sosio et al. 2000; Miao et al. 2005; Galm and Shen 2006) . ESAC vectors could assist in various genetic manipulations of the biosynthetic pathways through cloning of entire clusters and their heterologous expression in a host amenable to in vivo genetic manipulation. However, at the time ESAC and related vectors were developed, rapid whole genome sequencing was not available, and methods for creating large-insert DNA libraries were not well developed; thus, the use of ESAC vectors could require assembling large DNA inserts from cosmids through multiple rounds of homologous recombination (Sosio, Bossi and Donadio 2001) .
While YAC, BAC and PAC tools are no longer necessary with NGS technology, their use is witnessing a renaissance thanks to the increasing number of deposited genome sequences, improved bioinformatics tools for BGC identification and improved methods for library construction. Although the successful heterologous expression of an entire BGC remains unpredictable, several cloning and heterologous host systems have been developed, providing ample choices (Alduina and Gallo 2012; Ongley et al. 2013; Nah et al. 2017) .
In this minireview, we will provide an overview of the vectors that have been developed for cloning large BGC and the strategy that has been used for their successful heterologous expression. Because of space constraints, this overview will be limited to actinomycete-derived metabolites. Nonetheless, many of the principles developed for actinomycetes have been successfully employed for other important hosts such as E. coli, Pseudomonas putida, Bacillus subtilis (Ongley et al. 2013; Rutledge and Challis 2015; Nah et al. 2017) .
POSSIBLE APPROACHES FOR HETEROLOGOUS EXPRESSION
Heterologous expression of an entire BGC represents one of the most promising approaches to overcome the hurdle of developing a gene transfer system for the native producer. It not only allows the production of a desired metabolite in a host amenable to genetic manipulation, but it can also lead to the development of general rules for efficient production of different classes of metabolites in defined host(s), without the need to devise ad hoc conditions for cultivation of or establish metabolic models in different hosts (Ongley et al. 2013) .
Vectors suited for heterologous expression of entire BGCs must be effectively mobilized into the chosen host(s), where they can be stably maintained, possibly without antibiotic addition to select for construct presence. Normally, this is achieved by site-specific integration of the incoming DNA by a vectorencoded integrase. In addition, the ability to accommodate large DNA inserts is an important requisite, since many BGCs are too large to fit within the cloning capacity of cosmid and fosmid vectors. Various approaches for heterologous expression of secondary metabolite biosynthetic pathway have been pursued in the last few years, and they made use of different E. coliStreptomyces shuttle vectors based on bacterial or P1-derived artificial chromosomes (Jones et al. 2013; Alt and Wilkinson 2015; Nah et al. 2015; Kepplinger et al. 2017; Pyeon et al. 2017) , of transformation-associated recombination (TAR; Yamanaka et al. 2014) and of integrase-mediated recombination (IR; Du et al. 2015) . These approaches are schematized in Fig. 1 . Table 1 lists the key features of the BAC, PAC, TAR and IR vectors used over the last decade for cloning and heterologous expression. Figure 2 shows examples of secondary metabolites heterologously expressed with the herein described approaches.
CLONING SYSTEMS FOR LARGE BGCs
The TAR system One of the early reports made use of RecET-mediated linearplus-linear homologous recombination and was used successfully to clone BGCs of 10-52 kbp from the genome of Photorhabdus luminescens and express two of them in E. coli (Fu et al. 2012; Ongley et al. 2013) . Based on this system, TAR was used for direct cloning of 20-73 kbp BGCs (Yamanaka et al. 2014) . The TAR system exploits the high level of homologous recombination in the yeast Saccharomyces cerevisiae. Recent TAR cloning vectors, such as pCAP01, consist of three elements: for yeast, an autonomous replicating sequence (ARS), a plasmid maintenance element (CEN) and an auxotrophic marker; for E. coli, a pUC ori that could stably carry inserts larger than 50 kbp and an oriT for conjugation; and for actinobacteria, an attP-int system for chromosomal integration (Fig. 3) . The capture vectors are also provided with an antibiotic resistance gene for selection of both E. coli and actinomycete recombinants (Yamanaka et al. 2014; Tang et al. 2015; Bilyk et al. 2016) . In this way, the target DNA can be assembled in yeast, isolated and introduced into E. coli, and then directly conjugated into the desired actinomycete, where it can be maintained after chromosomal integration (Table 1) . The TAR strategy relies on the 'capturing vector', which contains the two distal ends of the target DNA segment. The linearized capturing vector and the restriction enzyme digested genomic DNA are assembled into yeast, where the target DNA fragment is captured by homologous recombination (Fig. 1B) .
Examples of BGCs isolated by the TAR technique using pCAP01 vector and expressed in a heterologous host include (Table 2 ) the 73-kbp taromycin A BGC from a marine Saccharomonospora sp. (Fig. 2) , which was successfully expressed in Streptomyces coelicolor M1146 after deleting the gene for a LuxR-type regulator (Yamanaka et al. 2014) ; the 21-kbp enterocin BGC from Salinispora pacifica, which was expressed in two different Streptomyces strains (Bonet et al. 2015) ; and the 44-kbp nataxazole BGC from Streptomyces sp. TÜ6176 which led to production of the nataxazole precursor AJ9561 in S. lividans JT46 (Cano-Prieto et al. 2015) . In addition, Jordan and Moore (2016) identified the ammosamide BGC through direct cloning in pCAP01 and heterologous expression in S. coelicolor M512, demonstrating the complex set of biosynthetic genes necessary for biosynthesis of this pyrroloquinoline alkaloid through gene deletions in the heterologous host (Table 2) . A modified version of pCAP01 has been utilized to clone PKS-NRPS hybrid BGCs from two Salinispora strains and to identify thiotetronic acid antibiotics as their products after expression in S. coelicolor M1152 (Tang et al. 2015) (Fig. 2) . The vector pCLY10, another TAR shuttle vector, was utilized to clone the 36-kbp grecocycline BGC from Streptomyces sp. Acta 1362 and to express it in Staphylococcus albus J1074, where several grecocycline congeners were detected (Bilyk et al. 2016 ).
An in vitro variation of the TAR system is represented by CATCH (Cas9-assisted targeting of chromosome). The method is based on the in vitro application of RNA-guided Cas9 nuclease (Jiang and Zhu 2016) , which can cleave in vitro intact bacterial chromosomes embedded in agarose plugs at target sequences. The resulting fragments can be subsequently ligated through Gibson assembly (Gibson et al. 2009) (Fig. 1C) . This system was used to clone the 36-kbp jadomycin BGC from S. venezuelae and the 32-kbp chlortetracycline BGC from S. aureofaciens (Jiang et al. 2015) .
The IR system
Recently, a strategy was developed based on integrase-mediated site-specific recombination and used for simultaneously engineering a Streptomyces genome and cloning a BGC. The attP-int loci from phages C31 and BT1 have been used to construct versatile vectors which can integrate into different attB sites in Streptomyces (Bierman et al. 1992; Gregory, Till and Smith 2003; Gonzalez-Quiñonez et al. 2016) . To increase the diversity of the BT1 attP-attB pair, the central dinucleotide sequence of attB and attP was mutated (Du et al. 2015) . Using a non-replicating and a temperature-sensitive replicon, homologous recombination was used for targeted integration of the mutated attB and attP at the distal ends of the BGC of interest. Then, BT1 Int excised the target region from the chromosome, and the plasmid containing the BGC was recovered at the permissive temperature (Fig. 1D) . This system was validated by cloning the 25-kbp actinorhodin (act) BGC, the 45-kbp napsamycin BGC and a 157-kbp segment containing the daptomycin BGC (Fig. 2) . The fidelity of the procedure was confirmed by complementation of a act S. coelicolor mutant (Du et al. 2015) .
Escherichia coli-Streptomyces shuttle BAC/PAC vectors
Pioneering work with BAC and PAC vectors demonstrated the capacity to clone DNA inserts approaching 200 kb in length, which could be stably maintained in a heterologous Streptomyces host (Sosio et al. 2000; Martinez et al. 2004; Miao et al. 2005) . The early E. coli-Streptomyces shuttle vectors pBELOBAC and pPAC-S1 have since been replaced by several improved variants, such as pStreptoBAC V, pSBAC and pESAC13, which contains the oriT site for conjugative transfer into actinomycetes and have been successfully used for heterologous expression (Table 1, Table 3 and Fig. 3) . for maintenance and manipulation in E. coli (pUC ori) and for chromosomal integration and expression in actinobacteria (attP-int system) (Yamanaka et al. 2014) ; (B) pESAC13 was constructed by inserting a 760-bp DNA fragment containing oriT from the RK2 replicon (Simon, Priefer and Pühler 1983) into the unique BstXI site of pPAC-S1 (Sosio et al. 2000) . pESAC13A was constructed by replacing through Red/ET recombineering the aph(3)II gene (conferring kanamycin resistance) in pESAC13 with the aac(3)IV gene (conferring apramycin resistance) from pSET152 (Bierman et al. 1992 PK = polyketide; NRP = non-ribosomal peptide; RiPP = ribosomally synthesized, posttranslationally modified peptide; a after cluster refactoring; b derivative of pCAP01 characterized by the counterselectable marker URA3 under the strong pADH1 promoter; see Tang et al. (2015) for further details; c shuttle vector for E.coli-yeast-actinomycetes (Bilyk et al. 2016 ).
The vector pStreptoBAC V, which contains the C31 attPint system (Table 1) , was used for cloning the 128-kb segment containing the BGC for the NRPS-made lipopeptide daptomycin (Fig. 2) and for its analog A21978C from S. roseosporus NRRL 11379, and their expression in different S. lividans strains (Miao et al. 2005; Penn et al. 2006) . Although the antibiotic yields were low, production was improved by deleting the act BGC and by medium optimization (Penn et al. 2006) . Later, pStreptoBAC V was used for cloning and heterologous expression of the 65-kb iso-migrastatin BGC in different Streptomyces hosts (Feng et al. 2009 ).
The pSBAC vector, which contains the BT1 attP-int system (Table 1) , was used for cloning the 90-kb PKS-NRPS BGC for the macrolide meridamycin (Fig. 2) from Streptomyces sp. NRRL 30748 and its heterologous expression in S. lividans K4-114, a act strain. Production of meridamycin and its 3-nor analog was observed only upon inserting the ermE * promoter in front of the NRPS-PKS genes, and it was enhanced by feeding the biosynthetic precursor diethylmalonate (Liu et al. 2009 ). The pS-BAC vector has been subsequently used for cloning two PKS I BGCs, for tautomycetin (80 kb from Streptomyces sp. CK4412) and pikromycin (60 kb from S. venezuelae ATCC 15439), applying the plasmid rescue technique (Nah et al. 2015; Pyeon et al. 2017) . For tautomycetin, while introduction of the pSBAC in naïve strains led to similar production levels as in the original host, tandem transfer of the constructs in Streptomyces sp. CK4412 or in S. coelicolor M145 dramatically increased tautomycetin production (Nah et al. 2015) . Similarly, when the pikromycin BGC was tandemly introduced into S. lividans TK21, production of 10-deoxymethynolide and pikromycin was observed, at levels 1.6-to 1.8-fold the parental strain .
Over the last few years, there have been several reports of heterologous expression of a variety of natural products, mostly generated by large modular PKS and NRPS systems, in different Streptomyces hosts using the PAC derivative pESAC13 (Table 3 ). The pESAC13 vector is a derivative of pPAC-S1 (Sosio et al. 2000) . It contains an oriT locus for conjugal DNA transfer from E. coli and comes in two flavors: the original pESAC13, used for all work listed in Table 3 , and the pESAC13A variant, carrying an additional selection marker for apramycin resistance (Fig. 3) . The papers listed in Table 3 have enabled production of the desired metabolites in a genetically tractable host with sometimes yield improvements as compared to the native host or production of new congeners. It should be noted that all/most of the BGCs listed in Table 3 were isolated after screening large insert libraries in pESAC13 custom-produced by the specialized company Bio S&T (Montreal, Canada; www.biost.com). Jankowitsch et al. (2012) expressed the 100-kb roseoflavin BGC from S. davawensis JCM 4913 (Fig. 2) in S. coelicolor M1152. The S. tsukubaensis NRRL 18488 BGC for FK506 (tacrolimus) (Fig. 2) , a clinically important immunosuppressant, was introduced as part of a 130-kb ESAC clone into four different S. coelicolor strains (M512, M1146, M1152 and M1154). These strains all produced FK506 with significant yield improvements upon overexpression of a BGC-associated positive regulator (Jones et al. 2013) . The utility of heterologous expression in S. coelicolor M1152 was also demonstrated for simocyclinone produced by S. antibioticus Tü6040 (Fig. 2) . While the native host is particularly challenging for genetic manipulation, manipulation and functional analysis of the symocyclinone, BGC was possible in the heterologous system (Schäfer et al. 2015) .
Upon screening an ESAC library of S. toyocaensis genomic DNA, Yim et al. (2016) identified a clone with a 140-kb insert containing the complete BGC for the glycopeptide A47934 (Fig. 2) . After mobilizing it into S. coelicolor M1146, these authors were able to further decorate the A47934 scaffold following introduction of additional tailoring genes (Yim et al. 2016) . Heterologous expression of azalomycin, a 36-membered aminopolyol macrolide, in S. lividans TK24 was observed using an ESAC clone carrying a 146-kbp insert (Hong et al. 2016) . Production of azalomycin was achieved when the heterologous host was fed 4-guanidinobutyramide, a specific precursor of the azalomycin starter unit (Hong et al. 2016) . Also, the heterologous host was able to methylate the guanidino group, notwithstanding that the cloned fragment did not contain the required methylase (Hong et al. 2016) . The last reported example is related to the (Kepplinger et al. 2017) (Fig. 2) . This represents so far the largest gene cluster to be expressed in a heterologous host and one of the few examples of successful intergeneric expression. Recently, the broad-host range, transferable BAC vectors pSMART-BAC-S and pBAC-SBO have been developed by Lucigen (www.lucigen.com). These vectors have been used for the efficient preparation of two environmental libraries, highlighting their potential for discovering new compounds from the metagenome (https://www.lucigen.com/docs/ posters/Soil-Metagenomics-Jan-13-SLAS.pdf).
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
A variety of ingenious cloning systems and vectors have been devised to harbor DNA fragments large enough to carry entire BGCs. Of the systems described above, the TAR, CATCH and IR systems require precise knowledge of the BGC(s) of interest. While conceptually simple, the IR approach requires an original producer that is genetically accessible, a requisite that limits this method to strains that have been well characterized. The TAR and CATCH systems make use of in vivo or in vitro recombination, respectively, and thus bypass the need to genetically access the native producer. These systems may be the best approach when the objective is mobilization of a single, large BGC. However, both systems are cluster-specific and cloning of multiple clusters from a single source would require working in parallel with different constructs. In contrast, BAC and PAC DNA libraries do not require a priori knowledge of the BGC(s) and can in principle provide the entire repertoire of BGCs from a single strain. However, the quality of the DNA library is essential, especially for large BGCs: ideally, the average insert size of the library should be larger than the target BGC, and the library should consist of about 10 genomic equivalents.
Potentially, these libraries can also provide a way for accessing BGCs from complex environments (i.e. metagenomics DNA libraries). Expression of environmental DNA for antibiotic discovery is an attractive proposition, but up to now only few BGCs, usually of the small size, have been expressed (Ongley et al. 2013; Katz, Hover and Brady 2016) . Interestingly, BGCs have been built from smaller fragments using the TAR system, leading to the assembly of 90-kb BGCs (Kim et al. 2010; Feng, Kallifidas and Brady 2011) .
At the moment, the E. coli-Streptomyces shuttle BAC/PAC vectors seem the most suitable systems for cloning and expressing large BGCs. Using current recombination techniques, cloned clusters of interest can be retrofitted with desirable selectable markers, maintenance system or compound-modifying genes, thus adapting them to the specific needs of the investigator. The ease of generating whole genome sequences and the highquality, large insert libraries that can be made in pESAC13 and similar vectors make these systems attractive for analyzing genetically intractable strains that are however (potential) producers of a large number of bioactive metabolites.
